BrainStorm enrolls first patients in advanced ALS stem cell trial

Reuters – BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

The Phase 3 clinical trial is expected to include about 200 patients and will be conducted at six ALS clinical sites in the United States, Israel-based BrainStorm said on Monday.

The company is developing a treatment made from adult stem cells for patients with ALS, a neuro-degenerative disease. The treatment, called NurOwn, has been administered to 75 ALS patients in clinical trials in the United States and Israel.

Read more at Reuters.

News Image
embryonic stem cells
Image Citation